Holen Sie sich die Stockscreener-App
27.16
2.86%
-0.80
Vorhandelsmarkt:
28.00
0.84
+3.09%
Schlusskurs vom Vortag:
$27.96
Offen:
$27.97
24-Stunden-Volumen:
203.07K
Relative Volume:
0.69
Marktkapitalisierung:
$1.23B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-161.15M
KGV:
-7.3111
EPS:
-3.7149
Netto-Cashflow:
$-138.61M
1W Leistung:
-7.21%
1M Leistung:
-5.46%
6M Leistung:
+33.46%
1J Leistung:
+0.00%
1-Tages-Spanne:
$26.73
$28.57
1-Wochen-Bereich:
$26.73
$31.28
52-Wochen-Spanne:
$12.24
$33.28
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Firmenname
Maplight Therapeutics Inc
Sektor
Branche
Telefon
650-839-4360
Adresse
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
27.16 | 1.27B | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Needham | Buy |
| 2026-04-07 | Eingeleitet | TD Cowen | Buy |
| 2026-03-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-11-21 | Eingeleitet | Jefferies | Buy |
| 2025-11-21 | Eingeleitet | Leerink Partners | Outperform |
| 2025-11-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-21 | Eingeleitet | Stifel | Buy |
Alle ansehen
Maplight Therapeutics Inc Aktie (MPLT) Neueste Nachrichten
MapLight Therapeutics (MPLT) Surges 3.31% as Positive Momentum BuildsHull Moving Average - newsline.com
MPLT Q1 2026 Earnings: EPS Misses Estimates by 20% as Pre-Revenue Biotech Continues Clinical Progress - newsline.com
MapLight Therapeutics (MPLT) Drops Over 6% as Key Support Level NearsVWAP Breakout - newsline.com
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data - AOL.com
MPLT Maintained by Stifel -- Price Target Raised to $36.00 - GuruFocus
Stifel Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Raises Target Price to $36 - Moomoo
Stifel raises MapLight Therapeutics price target on drug potential By Investing.com - Investing.com Canada
MPLT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineNew Analyst Coverage - newsline.com
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - AOL.com
MPLT Options Volatility — NASDAQ:MPLT - TradingView
MPLT Options Chain — NASDAQ:MPLT - TradingView
MapLight Stock Slips Ahead of August Drug Update - Bez Kabli
MPLT Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Development SpendingEarnings Call Q&A - The Legal Advocate
MPLT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
MPLT Initiated Coverage by UBS -- Rating Set to Buy, Target at $48 - GuruFocus
MapLight Therapeutics Rises 2.4%, Nearing Key Resistance Level (MPLT)Resistance Breakout Stocks - The Legal Advocate
MapLight Therapeutics (MPLT) Tests Key Support After 1.8% DeclineSeasonality Effect - The Legal Advocate
Nan Fung Group Holdings Ltd's MapLight Therapeutics Inc(MPLT) Holding History - GuruFocus
MPLT Initiated Coverage On by Craig-Hallum -- Rating Set to Buy - GuruFocus
MapLight Therapeutics (MPLT) Q1 2026 Stumbles — EPS $-1.34 Misses TargetPro Trader Picks - Newser
Craig-Hallum initiates MapLight Therapeutics stock with buy rating By Investing.com - Investing.com Canada
MapLight Therapeutics Q1 2026 Earnings: Wider Loss than Anticipated, Yet Shares Climb on Pipeline OptimismRevenue Surprise History - The Legal Advocate
Analyst Reiterates Buy on MapLight, Maintains $37 Price Target on Confidence in ML-007 and Pipeline Upside - TipRanks
MapLight's psychosis drug could deliver billion-dollar upside, says analyst - MSN
MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock By Investing.com - Investing.com Nigeria
MapLight Therapeutics Insider Sold Shares Worth $3,215,000, According to a Recent SEC Filing - Moomoo
MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock - Investing.com
MapLight Therapeutics (MPLT) CEO sells 118K shares in pre-planned trades - Stock Titan
MapLight Therapeutics, Inc.Common Stock (NQ: MPLT - The Chronicle-Journal
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - The Motley Fool
Buy Rating Reiterated on Clinical Catalysts and Strong Cash Runway; $37 Price Target Unchanged - TipRanks
T. Rowe Price (NASDAQ: MPLT) discloses 7.4% position in MapLight Therapeutics - Stock Titan
A Quick Look at Today's Ratings for MapLight Therapeutics(MPLT.US), With a Forecast Between $35 to $45 - Moomoo
MPLT SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
MapLight Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36, Implies 23% Upside - TradingView
MapLight (MPLT) Reports Progress in Clinical Trials and Early-St - GuruFocus
MapLight Therapeutics Expands Pipeline Amid Rising Quarterly Losses - TipRanks
MapLight Therapeutics 1Q Loss/Shr $1.34 >MPLT - Moomoo
TradingKey - TradingKey
[10-Q] MapLight Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
MapLight Therapeutics (MPLT) widens Q1 loss as key Phase 2 readouts near - Stock Titan
What $395M in cash means for MapLight’s schizophrenia, autism trials - Stock Titan
MapLight Therapeutics (MPLT) Q4 2025 Earnings: Miss Sparks ConcernNet Profit Margin - newsline.com
Finanzdaten der Maplight Therapeutics Inc-Aktie (MPLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maplight Therapeutics Inc-Aktie (MPLT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hanson Kristopher | General Counsel |
May 11 '26 |
Sale |
30.13 |
13,917 |
419,263 |
162,331 |
| Kroeger Christopher A. | Chief Executive Officer |
May 08 '26 |
Sale |
27.69 |
34,411 |
952,835 |
1,526,309 |
| Kroeger Christopher A. | Chief Executive Officer |
May 07 '26 |
Sale |
28.65 |
20,100 |
575,797 |
1,560,720 |
| Kroeger Christopher A. | Chief Executive Officer |
May 11 '26 |
Sale |
30.11 |
13,980 |
421,002 |
1,512,329 |
| Foff Erin Pennock | Chief Medical Officer |
May 07 '26 |
Sale |
28.54 |
4,438 |
126,640 |
346,059 |
| Lillie James Woodruff | Chief Scientific Officer |
May 07 '26 |
Sale |
28.28 |
721 |
20,390 |
242,729 |
| Setia Vishwas | Chief Financial Officer |
May 04 '26 |
Sale |
28.11 |
14,904 |
418,930 |
377,723 |
| Setia Vishwas | Chief Financial Officer |
May 05 '26 |
Sale |
28.20 |
10,903 |
307,444 |
366,820 |
| Setia Vishwas | Chief Financial Officer |
May 06 '26 |
Sale |
28.24 |
10,564 |
298,345 |
356,256 |
| Foff Erin Pennock | Chief Medical Officer |
May 06 '26 |
Sale |
28.76 |
24,052 |
691,749 |
350,497 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):